Stock Traders Purchase Large Volume of BioCryst Pharmaceuticals Call Options (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw unusually large options trading activity on Monday. Investors acquired 2,478 call options on the stock. This is an increase of 59% compared to the average daily volume of 1,554 call options.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $5.26 on Wednesday. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.96. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -4.46 and a beta of 1.96. The business has a 50 day moving average price of $4.90 and a two-hundred day moving average price of $5.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.06. The firm had revenue of $92.80 million for the quarter, compared to the consensus estimate of $85.62 million. The company’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.28) EPS. Equities analysts expect that BioCryst Pharmaceuticals will post -0.69 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several large investors have recently made changes to their positions in BCRX. Fifth Third Bancorp lifted its stake in BioCryst Pharmaceuticals by 17,500.0% during the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,500 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 2,388 shares in the last quarter. Quarry LP acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $54,000. Tower Research Capital LLC TRC boosted its stake in shares of BioCryst Pharmaceuticals by 131.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 5,912 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth $64,000. Institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on BCRX. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. Needham & Company LLC restated a “buy” rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Finally, JMP Securities raised their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $14.00.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.